shares of acumen pharmaceuticals on tuesday extended mondays afterhours losses following the commencement of an underwritten public offering of 100 million shares at 225 pm et shares were down 21 to 768 the stock has however surged 39 since the year began and climbed 24 in the past twelve months the charlottesville va clinicalstage biopharmaceutical company intends to use proceeds from the offering to fund the phase 2 portion of a future potential phase 23 trial of the experimental immunotherapy acu193 to fund research and development and for working capital and other general corporate purposes